VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
已取消10由 有空来看你 发布于 2024/7/25 19:38:29
DOI:10.1016/j.annonc.2024.04.003
作者:H. Li , J. Liu , Y. Liu , Q. Ouyang , S. Wang , Z. Tong , Y. Teng , T. Sun , X. Wang , J. Cheng , X. Zhou , L. Fanfan , M. Yan , J. Nie , C. Ye , Z-M. Shao , Y. Wang , X. Yang , E. Song
文献类型:期刊论文
补充材料:只需要正文